The primary objective of this first‐in‐human study was to assess the safety and tolerability of DS‐1205c in combination with gefitinib in metastatic or unresectable EGFR‐mutant NSCLC subjects and to determine the recommended dose of DS‐1205c in combination therapy for expansion study. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.